XPOVIO® (selinexor) is the first and only XPO1 inhibitor approved in Hong Kong XPOVIO® has received regulatory approvals in 41 countries and regions including the United States, Israel, the United Kingdom, the European Union (the 27 member countries including France and Italy), Canada,…